Protocol Ledger

NCT05431088 · Phase II/III · RECRUITING

A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

Interventional Phase II/III clinical trial protocol NCT05431088 sponsored by Pfizer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-22 Enrollment: 389 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05431088
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)389 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05431088
Protocol FieldVerified Registry Value
NCT IdentifierNCT05431088
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment389 participants (ESTIMATED)
Registered Start Date2022-09-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05431088
Hospital Research SiteLocationSite Profile
Connecticut Children's Medical CenterHartford, CTOpen Hospital Dossier ->
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI